Testosterone improves erectile function in hypogonadal patients with venous leakage

Area of Science:

• Endocrinology
• Urology
• Andrology

Background:

• Hypogonadism is associated with erectile dysfunction (ED).
• Standard phosphodiesterase type 5 inhibitor therapies are not always effective for ED in hypogonadal men.
• Long-acting testosterone undecanoate offers a sustained therapeutic option.

Purpose of the Study:

• To evaluate the efficacy of long-acting testosterone undecanoate in hypogonadal men with ED.
• To assess improvements in erectile function and penile hemodynamics.
• To determine the impact on venous leakage.

Main Methods:

• 29 hypogonadal men with ED (age 32-65) received injectable testosterone undecanoate (Nebido protocol).
• Penile blood flow assessed using duplex Doppler ultrasonography.
• Venous leakage confirmed by pharmacocavernosography and MRI in subsets of patients.
• Plasma testosterone and International Index of Erectile Function (IIEF-5) scores monitored at baseline and 18/30 weeks.

Main Results:

• Testosterone levels increased significantly from baseline (7-11.8 nmol/L) to 18 and 30 weeks (18 and 21.5 nmol/L).
• 20 out of 29 patients showed marked improvement in erectile function (IIEF-5 scores) after 18 and 30 weeks.
• Improvements in erectile function correlated with a reduction in venous leakage.

Conclusions:

• Long-acting testosterone undecanoate therapy is effective for improving erectile function in hypogonadal men with ED.
• Testosterone replacement therapy can address underlying venous leakage contributing to ED.
• This therapeutic approach offers a viable solution for ED refractory to PDE5 inhibitors.